ArticleInternational journal of molecular medicine2020
miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1.
Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The expression profiles and roles of microRNAs in cardiac glucose metabolism.Frontiers in endocrinology · 2025Pooled it
- Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Association of rs2910164 in miR-146a with type 2 diabetes mellitus: A case-control and meta-analysis study.Frontiers in endocrinology · 2022Pooled it
- The role of impaired mitochondrial function in neurological manifestations of mitochondrial diseases.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Transcriptomic insights into renal osmoregulation and environmental adaptation in two hammerhead shark species (Sphyrna zygaena and Sphyrna lewini).Fish physiology and biochemistry · 2026Article
- Physical exercise and miR-146a in type 2 diabetes and obesity: a narrative review.Molecular biology reports · 2026Review
- Exercise and Skeletal Muscle-Derived Extracellular Vesicles: Their Cargo, Release, and Role in Metabolic Regulation.Journal of extracellular biology · 2026Review
- Mitochondrial dysfunction-driven inflammation and β-Cell apoptosis in type 2 diabetes mellitus: mechanistic insights and therapeutic implications.Molecular biology reports · 2026Review
- MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5.Cancer research communications · 2026Article
- miR-130a-3p promotes fiber type transition and improves exercise tolerance in mice.Biological research · 2025Article
- Pancreatic MicroRNAs inBiomolecules · 2025Article
- The role of canopy family proteins: biological mechanism and disease function.Molecular biology reports · 2025Review
- Causal and mediating effects of lipid and facial aging: association study integrating GWAS, eQTL, mQTL, and pQTL data.Lipids in health and disease · 2024Article
- Role of liquid-liquid phase separation in cancer: Mechanisms and therapeutic implications.Cancer innovation · 2024Review
- Inhibiting miRNA-146a suppresses mouse gallstone formation by regulating LXR/megalin/cubilin-media cholesterol absorption.Heliyon · 2024Article
- Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review.Cancer chemotherapy and pharmacology · 2024Review
- Establishment of a Mitochondrial Metabolism-Related Diagnostic Model in Schizophrenia Based on LASSO Algorithm.Psychiatry investigation · 2024Article
- Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease.Biomedicines · 2024Article
- Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.World journal of gastroenterology · 2024Article
- Role of Decreased Expression of miR-155 and miR-146a in Peripheral Blood of Type 2 Diabetes Mellitus Patients with Diabetic Peripheral Neuropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non‑alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Increasing evidence has shown that microRNAs (miRNAs) play a vital role in the progression of NAFLD. The aim of the present study was to examine the expression level and roles of miR‑146a in fatty liver of high‑fat diet (HFD) and ob/ob mice and fatty acid‑treated hepatic cells using RT‑qPCR and western blot analysis. The results showed that the expression of miR‑146a was significantly decreased in the livers of high‑fat diet (HFD) and ob/ob mice and free fatty acid‑stimulated cells by RT‑qPCR. Overexpression of hepatic miR‑146a improved glucose and insulin tolerance as well as lipid accumulation in the liver by promoting the oxidative metabolism of fatty acids. In addition, the overexpression of miR‑146a increased the amount of mitochondria and promoted mitochondrial respiration in hepatocytes. Similarly, inhibition of miR‑146a expression levels significantly reduced mitochondrial numbers in AML12 cells as well as the expression of mitochondrial respiration related genes. Additionally, MED1 was a direct target of miR‑146a and restoring MED1 abolished the metabolic effects of miR‑146a on lipid metabolism and mitochondrial function. Therefore, results of the present study identified a novel function of miR‑146a in glucose and lipid metabolism in targeting MED1, suggesting that miR‑146a serves as a potential therapeutic target for metabolic syndrome disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.